The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease’s management

Urinary bladder cancer (BCa) accounts for about 7% of all new cancers in the USA with 81,190 estimated new cases and 17,240 deaths in 2018 (1). Approximately 75% of the new diagnoses BCa will be non-muscle-invasive BCa (NMIBC) (2) affected by disease recurrence and progression rates of approximately 60% and 20%, respectively (3).